A recent publication in The Lancet by Cordeiro and colleagues reported levels of IgM for Zika (ZIKV) and dengue (DENV) viruses in serum and cerebrospinal fluid (CSF) of 31 infants born with microcephaly in Brazil.
I. Introduction
Zika virus (ZIKV) has recently emerged from relative obscurity to the forefront of the global health agenda in 2015 due to a potential association with microcephaly and other congenital malformations. 2 Diagnosis of ZIKV can be difficult due to a short window to capture active viremia, and crossreactivity with other flaviviruses including Yellow fever virus (YFV) and dengue (DENV) in many serological assays. Several sets of recent case reports have specifically highlight the difficulties with both IgG and IgM cross-reactivity using ELISA. 3, 4 Several studies have examined the serology of ZIKV in adults, including pregnant women, but there has been limited data from neonates. The data reported by Cordeiro et.al fill an important gap; and cursory examination of their data suggest that there are differences in measured viral titers between sample sources from individual neonates, and between the cross-reacting antigens from a pool of all four DENV serotypes. In this report, statistical comparisons are made to more comprehensively understand these data and the potential relationships between measured serological parameters for these flaviviruses in the context of microcephaly in Brazil.
II. Methods
Full details of the patient population, and IgM serological assays are available in the original publication by Cordeiro et al. ; data were extracted from the table. 1 Comparison of population-level optical density (OD) ratios (titers) for each paired sample type was via a non-parametric signrank test. For multivariate models, the outcomes of ZIKV and DENV titers in CSF were used due to the inherent challenges in obtaining these samples relative to serum samples.
For reported regression coefficients, univariate models residuals were examined for outliers using Cooks' distance and leverage. All included variables were 'forced' into the model without explicit model building, but were examined for collinearity. Due to several outliers, reported R 2 values are from robust regressions; 5 however all conclusions are unchanged from ordinary least-squares (OLS)
regressions. For exploratory trends lines, lowess (locally weighted scatterplot smoothing 6 ), a nonparametric trend line method used with a bandwidth of 0.9.
All analyses used Stata 14.1 (College Station, TX, USA). All tests were two-tailed, with α = 0.05; no corrections were made for multiple comparisons.
III. Results
Comparisons of the population-level optical densities as median values for ZIKV and DENV ( Figure  1 , and Table 1) show no evidence of a statistically significant difference between DENV titer in the CSF and serum samples (p = 0.345). However comparison of the ZIKV antibodies in the same population shows evidence for a statistically significant difference (p = 0.016) between the two sets of paired CSF and serum samples. These differences are also clearly evident in Figure 1 , with little variance in the optical densities ratios for DENV, but higher values and greater variability in measured ZIKV titers.
Correlations between the titer of each sample type by antigen are show in Figure Univariate and multivariate analysis of ZIKV and DENV titers in CSF are presented in Tables 3  and 4 . With adjustment for sampling day after birth, the measured DENV titers in CSF have a positive statistically significant relationship with the ZIKV in CSF and DENV in serum, and a negative statistically significant relationship with ZIKV in serum.
After adjustment for covariates, this model predicts that for each single unit increase in DENV in CSF optical density ratio there will be a 0.277 (95% CI: 0.166 to 0.388, p < 0.001) unit increase in ZIKV in CSF; a 0.082 (95% CI: -0.153 to -0.011, p = 0.024) unit decrease in ZIKV in serum; and a 0.558 unit (95% CI: 0.376 to 0.741, P < 0.001) increase of DENV in serum. Days from birth was not significantly associated with DENV titer in CSF, with a coefficient of -0.007 (95% CI: -0.030 to 0.016, p = 0.553).
In sharp contrast to these results, for the outcome of ZIKV titer in CSF, none of the exploratory factors were significantly associated with outcome in multivariate models (all p > 0.30).
IV. Conclusions
This secondary analysis examines the relationship between ELISA titers for both DENV and ZIKV in paired serum and CSF samples. These results suggest contrasting compartmentalization of antibodies across the blood brain barrier, with statistically significantly higher levels of ZIKV antibodies in the CSF relative to serum in individual neonates.
Moreover, a limited exploratory analysis suggests these levels may remain higher in the weeks postbirth, assuming that each subject's levels are comparable at birth, while cross-reacting DENV titers in the CSF appear to decay through time.
The most striking finding is the independence of ZIKV titers in the CSF, whereas cross-reacting DENV antigens are closely correlated with other antigens in both sample types. This may be due to a ceiling effect in the serological assays, which could limit the dynamic range of these data in the absence of further serial dilutions. However, even with this caveat in mind, the titer levels in CSF are ca. 5-to 10-fold higher than those in serum, and ca. 15-fold higher than DENV titers in the CSF. This finding suggests that ZIKV titer in the CSF cannot be estimated directly from the titer in serum, or from cross-reacting DENV titers using this CDC assay at these dilutions.
There are limitations in this analysis: the sample size is limited; the subject inclusion/exclusion criteria are uncertain; other pathogens that may cause congenital malformations may not have been tested for; and a large number of potential covariates are unavailable (especially maternal IgM or IgG; maternal age; and gestational age).
Complex dynamics between serological assays for flaviviruses have been reported at the population level in other settings e.g. 7 and greater understanding and quantification of these trends may inform both ZIKV neuropathology studies and serological surveillance in areas with multiple co-circulating arboviruses.
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